ENSC · Ensysce Biosciences, Inc.
$0.26
+0.00 (+0.08%)
At close · Jul 27
Going-concern doubt
— flagged May 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These matters, among others, raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 15, 2026
Market Cap
$3.84M
Shares
14.69M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.26
Open$0.26
Day$0.26–0.28
52W$0.23–2.75
Avg vol 30d1.3M
Short int403K · 2.7% float · 1.0d
Short vol23%
Last earningsMay 18, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 15
Up next
Next earnings call
Mar 5, 2027
Est · unconfirmed
· in 31 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 18.7 · elevated
Equity put/call 0.66
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−70%
below
Price vs 50-day avg
−7%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
1%
near low
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−8%
trailing
6-month return
−64%
trailing
YTD return
−72%
this year
Relative strength
−71%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
2 of 15 funds reported for Jun 30 · net +155 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.74% of float · ▲ +121.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — mid 1-yr range
Squeeze score
49
elevated · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
EPS growth
+65%
Y/Y
Free cash flow
$-7.9M
Balance sheet
$4.3M
net cash
Quant / Vol
risk profile
Volatility
115%
annualized · 1-yr
Max drawdown
−90%
past year
ATR
9.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−70%
Bearish
Price vs 50-day avg
−7%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
1%
Bearish
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Accumulating
2 of 15 funds reported for Jun 30 · net +155 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.74% of float · ▲ +121.2% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — mid 1-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 1%
52-wk high $3
vs 200-day avg -70%
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ENSC
this stock
Ensysce Biosciences, Inc.
|
$3.84M | -71.6% | -2.8% | — | 2.7% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.3% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +5.7% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -13.5% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$55.61B | +5.7% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ENSC | -7.6% | -7.6% | -64.0% | -9.8% | -71.6% |
| SPY | -0.6% | +0.7% | +6.8% | -1.0% | +8.4% |
| vs SPY | -7.0% | -8.2% | -70.8% | -8.8% | -80.0% |